43.18
-1.68(-3.74%)
Currency In USD
| Previous Close | 44.86 |
| Open | 45.13 |
| Day High | 45.13 |
| Day Low | 42.94 |
| 52-Week High | 45.48 |
| 52-Week Low | 21.72 |
| Volume | 5.47M |
| Average Volume | 3.11M |
| Market Cap | 8.2B |
| PE | -12.13 |
| EPS | -3.56 |
| Moving Average 50 Days | 36.99 |
| Moving Average 200 Days | 31.41 |
| Change | -1.68 |
If you invested $1000 in BridgeBio Pharma, Inc. (BBIO) since IPO date, it would be worth $1,567.33 as of July 01, 2025 at a share price of $43.18. Whereas If you bought $1000 worth of BridgeBio Pharma, Inc. (BBIO) shares 5 years ago, it would be worth $1,423.2 as of July 01, 2025 at a share price of $43.18.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BridgeBio Raises $300 Million Through Partial Capped Monetization of BEYONTTRA® European Royalty
GlobeNewswire Inc.
Yesterday at 11:30 AM GMT
BridgeBio has received a $300 million upfront payment, strengthening the Company’s balance sheet, and supporting the launch of Attruby® and ongoing late-stage pipeline programsTransaction monetizes 60% of BridgeBio’s European royalties on the first $
BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET
GlobeNewswire Inc.
Jun 26, 2025 11:30 AM GMT
PALO ALTO, Calif., June 26, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced the Company will host an investor webina
BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025
GlobeNewswire Inc.
Jun 02, 2025 11:30 AM GMT
PALO ALTO, Calif., June 02, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that members of its management team will